Table 2.
Relationship between the presence or absence of osteosarcopenia and clinicopathological factors in all patients (n = 105)
| Factor | Osteosarcopenia, n (%) | ||
|---|---|---|---|
| Presence (n = 37) | Absence (n = 68) | p-value | |
| Sex, male/female | 23/14 | 50/18 | 0.22 |
| Median age, years | 69 | 65 | 0.13 |
| Performance status, 0/1–3 | 23/14 | 57/11 | 0.01 |
| Median Body mass index, kg/m2 | 20.5 | 21.85 | 0.01 |
| Preoperative chemotherapy, presence | 24 | 37 | 0.29 |
| Surgical method of surgery, total gastrectomy, presence | 17 | 36 | 0.54 |
| Median clinical tumor size (range), mm | 65 | 60 | 0.15 |
| Depth of tumor invasion, pT1/pT2–4 | 1/36 | 1/67 | 0.18 |
| Lymph node metastasis, pN0/pN1–3 | 6/31 | 21/47 | 0.10 |
| Pathological stage, II/III | 12/25 | 31/37 | 0.21 |
| Median CEA | 2.7 | 2.7 | 0.06 |
| Median CA19-9 | 11.6 | 9.9 | 0.89 |
| Median NLR | 2.95 | 2.18 | 0.25 |
| Median PNI | 45.3 | 47.5 | 0.40 |
| Median CAR | 0.03 | 0.03 | 0.31 |
| Median albumin, g/dL | 3.8 | 3.9 | 0.45 |
| Recurrence, presence | 30 | 32 | < 0.01 |
CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; NLR, neutrophil–lymphocyte ratio; PNI, prognostic nutritional index; CAR; C-reactive protein albumin ratio